HCl Technologies actions increased by 7.68 percent to ₹ 1,593.60 at 11.35 in the NSE on Wednesday, after its announcement of the fourth quarter results and its optimistic orientation of the FY26 that surpassed industry companions.
Several financial institutions have maintained a positive perspective of the actions. JPMorgan updated HCltech to “overweight” with an objective price of ₹ 1,750, citing value in action, with its dividends yield of 4 percent and 6 % of free cash flow performance. Nomura maintained a “purchase” rating, with an objective or ₹ 1,670, while Nuvama established an objective or ₹ 1,700. Morgan Stanley maintained a “equal weight” position, with an objective of ₹ 1,600, and Citi remained “neutral” with a price objective of ₹ 1,510.
The company reported an interannual increase of 8.1 percent in the net gain consolidated to ₹ 4,307 million rupees for the quarter ending in March 2025, while revenues increased 6.1 percent to ₹ 30,246 million rupees. For the full fiscal year 2024-25, HCltech recorded a 11 percent increase in net profits to ₹ 17,390 million rupees in revenues of ₹ 1.17,055 million rupees, 6.5 percent more than the previous year.
Despite the winds against the winds against Global Macroconomic, HCltech has projected a 2-5 percent growth in constant currency terms for fiscal year 2016. The company obtained new reserves worth $ 3 billion in the fourth quarter and declared a provisional dividend of ₹ 18 per capital action for the fiscal year 2016.
Posted on April 23, 2025
